AZN AstraZeneca PLC - American Depositary Shares

NASDAQ · Pharmaceuticals
$187.62
Price · May 20, 2026
52W Range
$69–$213
83% of range
Analyst Rating
BUY
36 analysts
Price Target
$224
+20% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—

AZN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$187.62
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$69 – $213

AZN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income —
EPS —
Free Cash Flow —
Margins —

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
AZN
Peer Median

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
AZN
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
AZN
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
AZN
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
AZN
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
AZN
Peer Median

Dividends Yield, payout ratio, dividend history, 5Y CAGR

Dividend Yield
—
Payout Ratio
—
5Y Div CAGR
—
Ex-dateAmount
Feb. 19, 2026$2.1530
Aug. 8, 2025$1.0300
Feb. 21, 2025$2.1000
Aug. 9, 2024$1.0000
Feb. 22, 2024$1.9700
Aug. 10, 2023$0.9300
Feb. 23, 2023$1.9700
Aug. 11, 2022$0.9300
Feb. 24, 2022$1.9700
Aug. 12, 2021$0.9000
Feb. 25, 2021$1.9000
Aug. 13, 2020$0.9000
Feb. 27, 2020$1.9000
Aug. 8, 2019$0.9000
Feb. 28, 2019$1.9000
Aug. 9, 2018$0.9000
Feb. 15, 2018$1.9000
Aug. 9, 2017$0.9000
Feb. 15, 2017$1.9000
Aug. 10, 2016$0.9000

AZN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 36 analysts
  • Strong Buy 13 36.1%
  • Buy 17 47.2%
  • Hold 4 11.1%
  • Sell 2 5.6%
  • Strong Sell 0 0.0%

12-Month Price Target

10 analysts · 2026-05-17
Median target $226.45 +20.7%
Mean target $224.49 +19.7%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
0.03%
Period EPS Actual EPS Est Surprise
March 31, 2026 $2.58 $2.59 -0.01%
Dec. 31, 2025 $2.12 $2.15 -0.03%
Sept. 30, 2025 $2.38 $2.35 0.03%
June 30, 2025 $2.17 $2.21 -0.04%
March 31, 2025 $2.49 $2.28 0.21%

AZN AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Grok NEUTRAL 0.75
↑ Bullish

AstraZeneca's oncology pipeline is firing on all cylinders with fresh approvals, fueling profit growth that could accelerate into 2026Q2. The EU nod for Imfinzi in early gastric cancers on March 25 opens new revenue streams in a high-margin franchise. ROE has risen to 21.8%, proving they're squeezing more earnings from their equity base amid improving efficiency. Net margin expanded to 16.17%, a clear sign costs are under control as sales ramp. Guggenheim's PT hike to 16,000 GBp underscores hedge fund conviction in the story.

↓ Bearish

AstraZeneca's balance sheet vulnerabilities could cap upside if drug launches falter or macro headwinds hit pharma. Current ratio at 0.88 falls short of 1.0, signaling potential strain in meeting short-term bills without extra financing. Debt-to-equity holds at 71.11, leveraging up returns but exposing the firm to interest rate spikes or cash burn. P/E near 30.6x leaves scant margin for error on earnings misses. Weekly closes dipping from 74.76 highs to 71.13 reflect fading momentum.

Claude NEUTRAL 0.62
↑ Bullish

AstraZeneca is firing on pipeline momentum while trading at a reasonable premium to the pharma peer set. The Imfinzi EU approval for early gastric cancer (March 2026) signals execution on oncology, their highest-margin franchise. EPS is up to 6.02 from 5.31 a year ago — that's 13% growth. Gross margin holds steady at 82%, which is fortress-level for a diversified pharma player. Guggenheim's price target lift to 16,000 GBp in mid-March suggests institutional conviction on the pipeline. My read: if the oncology portfolio keeps delivering approvals through 2026, the 30.6x P/E compresses as growth justifies the multiple.

↓ Bearish

The balance sheet is the real problem here. Debt-to-equity sits at 71%, which is high for a company that needs optionality for R&D bets and M&A. Current ratio of 0.88 means AZN has less than a dollar of liquid assets for every dollar of short-term obligations — that's tight. P/S of 4.96 is elevated even for pharma, and it's crept up from 4.36 just two quarters ago. My concern: if pipeline momentum stalls or a late-stage trial disappoints, the leverage becomes a liability. The stock has also drifted sideways since May despite the news flow — that's a warning flag on conviction.

Gemini NEUTRAL 0.70
↑ Bullish

AstraZeneca’s aggressive expansion into oncology is paying off, creating a robust pipeline that justifies its premium valuation. The recent EU approval for Imfinzi in gastric cancers highlights this momentum. The company is delivering a 21.8% ROE, which shows they are highly efficient at generating profit from the capital shareholders have invested. Furthermore, their gross margin sits at 81.9%. This indicates that for every dollar of medicine they sell, they keep over 80 cents before operating costs, proving they have immense pricing power in the global pharmaceutical market.

↓ Bearish

The company’s balance sheet is showing signs of strain that could limit its flexibility in an expensive R&D environment. A current ratio of 0.88 is my primary concern. This means the company currently has less than a dollar in liquid assets for every dollar of short-term debt, which is a tight spot for a firm needing massive cash injections for clinical trials. Additionally, the stock trades at a P/E of 30.6. This multiple suggests investors are paying a steep price for future growth that may not materialize if upcoming drug trials fail to deliver.

Chatgpt NEUTRAL 0.60
↑ Bullish

I think AZN has upside leverage from strong profitability and a durable earnings base. ROE TTM: 21.8%. That means AZN turns equity into profit efficiently, supporting shareholder returns. Net profit margin TTM: 16.17%. That shows AZN converts sales to profits at a healthy rate, backing steady cash flow for pipeline growth. EPS TTM: 6.02. That level provides a tangible earnings base to support a re-rating if Imfinzi and other assets gain traction.

↓ Bearish

I think AZN faces valuation and balance-sheet risks that could cap upside. P/E TTM: 30.65. That rich multiple leaves little room for error if growth slows. Debt/Equity: 71.11. That high leverage reduces financial flexibility and amplifies risk if margins retreat. Current ratio: 0.8792. That below-one liquidity signal can press AZN to tighten funding for R&D or pass through higher financing costs.

Round 2 — Responses & Rebuttals

Grok

Gemini, AstraZeneca's 0.88 current ratio isn't the R&D roadblock you describe because expanding margins provide the cash buffer. That ratio signals thin liquidity for short-term obligations. But net margin at 16.17% — up from 14.68% two quarters ago — converts more revenue straight to operating cash, fueling oncology trials without distress.

Claude

I need to push back on Grok's read of the price action. Grok says the weekly closes dipping from 74.76 to 71.13 reflect fading momentum, but that's a misread of the chart. We're looking at a 4.5% pullback over six weeks in a stock that's up from 66.44 in mid-May — that's a consolidation, not a collapse. More important: Grok is bullish at 0.75 confidence while citing the same 0.88 current ratio and 71% D/E that I flagged as real constraints. You can't call those balance-sheet risks minor and then buy the stock. If Imfinzi stumbles, that leverage becomes a noose, not a feature.

Gemini

Grok, your buy rating overlooks the structural danger in AstraZeneca's liquidity profile. You emphasize the oncology pipeline, but a current ratio of 0.88 means the company lacks enough cash to cover its immediate obligations. This is a critical vulnerability for a firm that must constantly fund expensive, high-risk clinical trials to maintain its growth trajectory. If the company hits a regulatory roadblock, that lack of liquid cushion could force them into unfavorable financing. I think betting on a buy while the balance sheet is this tight is simply too risky for 2026Q2.

Chatgpt

Claude, your point about the balance sheet is fair, but I think the market is pricing in AZN's pipeline momentum rather than a crisis. Debt/Equity at around 71% means the company uses debt to finance growth, which increases risk if rates rise or growth slows. AZN's cash flow and the high-margin Imfinzi franchise still provide resilience, but if approvals stall or costs rise, leverage could limit flexibility.

Round 3 — Final Rebuttals

G
Grok

Claude, your consolidation call misses the distribution signal in the chart — the pullback happened on elevated volume, pointing to institutional selling pressure. Volume hit 20.9 million shares on July 3 with a close at 69.45, well above the prior six-week average. That isn't quiet digestion; it's smart money exiting amid pipeline uncertainty. P/E holding flat at 30.6 through the dip means the market isn't buying the Imfinzi hype yet, reinforcing my buy if execution follows.

C
Claude

I want to push back on something Grok just said that no one challenged. Grok claims net margin expansion from 14.68% to 16.17% over two quarters means AZN is generating enough operating cash to fund oncology trials without distress. But that's not how pharma cash flow works. Net margin tells you what profit is left after all costs — it doesn't tell you when that cash actually arrives or how much is tied up in inventory, receivables, and working capital. More critically: a 0.88 current ratio means AZN owes more in the next 12 months than it has in liquid assets right now. That's a timing problem, not a margin problem. Margin expansion doesn't fix a liquidity squeeze. If a trial fails and cash burn accelerates, AZN has to refinance at higher rates or cut R&D — neither is painless.

G
Gemini

I disagree with Grok’s assessment that rising margins magically offset liquidity risks. A current ratio of 0.88 means the company has less than a dollar of liquid assets for every dollar of short-term debt, which is a structural bottleneck regardless of net profit margins. I want to shift the focus to the macro regime: the persistent strength of the USD is a silent killer for AstraZeneca. Because a massive portion of their revenue is earned in non-dollar currencies, a strong greenback erodes their reported earnings when converted back to USD. This currency headwind makes their 30.6 P/E valuation look increasingly fragile.

C
Chatgpt

I think, Claude, Grok, Gemini, we should widen the frame to macro and regulatory dynamics that actually move AZN's fair value. My read is the stock's near-term path is more sensitive to FX shifts and European price policies than just Q2 margins. The single metric to anchor this is P/E TTM about 30.6x. That implies investors are pricing in multi-year pipeline growth; if FX headwinds or price controls bite, the multiple could contract even if EPS stays steady.

Price Forecasts

Model 3M Target 6M Target Reasoning
G Grok 3M Target $76.00 6M Target $83.00 Reasoning I think AstraZeneca rerates higher by 2026Q2 as Imfinzi's EU launch catalyzes oncology revenue growth that offsets liquidity strains. The key catalyst is Q2 2026 earnings around late July 2026, where initial Imfinzi sales data should confirm uptake in gastric cancers. One big risk is a mid-2026 readout flop in a late-stage oncology trial, spiking cash needs. ROE at 21.8% means AZN turns every dollar of equity into over 21 cents of profit annually, justifying leverage and supporting my $83 target at a 33x P/E that prices in pipeline wins from today's $70.
C Claude 3M Target $72.50 6M Target $76.00 Reasoning AstraZeneca's oncology pipeline is real, but the balance sheet is the binding constraint — leverage and tight liquidity will cap upside unless cash generation accelerates materially. My thesis: the stock re-rates on Imfinzi revenue ramp and margin defense, but only if the company demonstrates it can service debt while funding trials. Catalyst: Q2 2026 earnings in late July showing sequential revenue growth in oncology and free cash flow positive despite R&D spend. Risk: a late-stage trial miss or European price pressure forces guidance cut, triggering multiple compression from 30.6x. At 30.6x P/E on 6.02 EPS, AZN is pricing in flawless execution — one stumble and the multiple contracts 15–20%, dragging price to 59–62. Near-term consolidation holds; 6-month target assumes modest pipeline validation and margin stability.
G Gemini 3M Target $72.50 6M Target $76.00 Reasoning My thesis is that AstraZeneca’s deep oncology pipeline will eventually overcome current liquidity fears, provided the company stabilizes its short-term debt obligations. A key catalyst for the six-month target is the Q3 earnings report, where I expect to see better-than-expected cash flow conversion from the Imfinzi franchise. The primary risk is a failure in a late-stage clinical trial, which would force a sharp re-pricing of the stock. Currently, the P/E of 30.6 suggests investors are paying a premium for future growth; this means any sign of pipeline stagnation will cause the multiple to contract rapidly, regardless of the company's strong gross margins.
C Chatgpt 3M Target $72.00 6M Target $76.00 Reasoning I think AZN can drift higher into 2026Q2 as pipeline momentum translates into earnings upside from Imfinzi and other high-margin franchises. Catalyst: the Q2 2026 earnings print with stronger Imfinzi revenue growth and pipeline updates. Risk: FX headwinds could derail earnings if currency moves bite. Current price is about 69.6; a move to 72 would imply a modest re-rating as approvals materialize, while 76 would price in stronger momentum, assuming continued execution and favorable overall margins.

Latest News Recent headlines mentioning this company

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.